申请人:Farmos-Yhtyma Oy
公开号:US04933359A1
公开(公告)日:1990-06-12
The invention provides 4(5)-substituted imidazole derivatives of formula ##STR1## and their acid addition salts, in which either X is --CH.sub.2 -- and R.sub.1 is --CN, --COOH, COO(lower alkyl), --CHO, --CO(lower alkyl), lower alkyl or 3 or 5 carbon atoms, lower alkenyl, or lower (hydroxy alkyl) or X is ##STR2## --C(:CH--R)-- or --CH(CH.sub.2 R)--, where R is hydrogen or lower alkyl, and R.sub.1 is lower alkyl, and R.sub.3 and R.sub.4 are each hydrogen, methyl, ethyl, methoxy, or halogen, and novel intermediates and processes for their preparation. These compounds, in particular when R.sub.1 is lower alkyl, lower alkenyl, or lower (hydroxy alkyl), possess valuable pharmacological properties and are useful especially as selective .alpha..sub.2 -receptor antagonists.
该发明提供了4(5)-取代咪唑衍生物的化学式##STR1##及其酸盐,其中X为--CH.sub.2--且R.sub.1为--CN,--COOH,COO(较低烷基),--CHO,--CO(较低烷基),较低烷基或3或5个碳原子,较低烯基,或较低(羟基烷基),或X为##STR2##--C(:CH--R)--或--CH(CH.sub.2 R)--,其中R为氢或较低烷基,R.sub.1为较低烷基,R.sub.3和R.sub.4分别为氢,甲基,乙基,甲氧基或卤素,并提供了其制备的新型中间体和方法。这些化合物,特别是当R.sub.1为较低烷基,较低烯基或较低(羟基烷基)时,具有有价值的药理特性,特别适用于作为选择性α2-受体拮抗剂。